Chronic Periodontitis Clinical Trial
Official title:
Evaluation of Antimicrobial Photodynamic Therapy in Multiple Applications as a Coadjuvant in the Surgical Therapy of Access to Scaling in Patients With Advanced Chronic Periodontitis
Chronic periodontitis is an infectious disease resulting in inflammation of the teeth support structures, progressive periodontal attachment loss and bone loss. The aim of this study is to evaluate the effects of antimicrobial photodynamic therapy (TFDA) in multiple applications as an adjunct to surgical periodontal therapy in patients with generalized severe chronic periodontitis. A total of twenty patients will be submitted to this split-mouth trial, receiving initial periodontal basic nonsurgical treatment that is scaling and root planing. After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications. All patients will be oral hygiene care and follow-up for 90 days. In the baseline period, basic post-therapy, 30 and 90 days after surgical therapy will be performed the clinical evaluation of plaque index, depth of probing pocket, level of clinical insertion relative and bleeding on probing, beyond the collection plate samples subgingival 40 for counting microbial species using the method of DNA-DNA hybridization checkerboard. For the same periods are also collected samples of gingival crevicular fluid for evaluating fluid volume (Periotron) and the levels of Interleukin 1 beta, Interleukin 10, MMP-8, tumor necrosis factor alpha, RANK-L and Osteoprotegerin (OPG). The data are statistically analyzed with the tests to the sample.
Non-Surgical Periodontal Therapy
Seven days prior to the non-surgical periodontal therapy, periapical radiographs will be
taken from the whole mouth of all patients. They will be set in an oral hygiene program (OHP)
according to their specific needs. In this program, patients will be instructed about an
effective self-performed plaque control, including information about the Bass Technique
(Bass, 1954) and interproximal cleaning with dental floss and interdental brushes. They will
be also motivated to brush the dorsal surface of the tongue once a day and will receive a
dentifrice that shall be used throughout the experimental period (Colgate Total®, Anakol Ind.
Com Ltda - Brazil's Kolynos - Colgate Palmolive Co., Sao Bernardo do Campo, SP, Brazil).
After the OHP, subjects will undergo the assessment of clinical periodontal parameters
previously described and the collection of subgingival plaque and GCF in selected sites
(baseline) will be performed. Shortly, patients will receive supragingival scaling and
coronal polishing with prophy cup on all the teeth present in the oral cavity. The
non-surgical periodontal therapy will initiate 7 days after the OHP and initial supragingival
scaling. Within 24 hours, a specialist in Periodontics will perform supra and subgingival
scaling and root planing of all teeth with periodontal involvement, using hand (Gracey
Curettes, Hu-Friedy, Chicago, IL, USA) and ultrasonic instruments. The instrumentation will
be performed on each quadrant until achievement of an adequate cleaning and root planing,
which will be verified with a dental explorer. Individuals will receive professional
prophylaxis biweekly during three months after the end of the nonsurgical periodontal
therapy. On biweekly follow-up visits, patient's cooperation will be monitored by verifying
the status of oral hygiene.
Surgical Periodontal Therapy
The flap operations are performed 8 weeks after the start of the basic preparation. Patients
will be monitored clinically and sites that present PS ≥ 5mm and SS presence will undergo
surgical therapy scraping retail. Surgical procedures will be performed by a specialist in
Periodontics. Initially patients will be subjected to extra-oral antisepsis with
chlorhexidine 2% and intraoral through mouthwash with chlorhexidine 0.12%. The region to be
operated infiltrative receive local anesthesia with lidocaine 2% solution, and 1: 100,000
epinephrine. The following will be performed intra-sulcular incision with a scalpel blade at
15C covering the site with PS ≥ 5mm and the adjacent teeth. A mucoperiosteal flap will be
performed until the exposure of the bone crest and subgingival deposits of calculation and /
or granulation tissue are removed by conventional Gracey curettes with RAR and Mini Five,
numbers 5/6, 7/8, and 11/12 13/14 (Hu-Friedy, Chicago, IL, USA) and ultrasonic devices.
Shortly after completion of the RAR starts to tfdA the operated region in the selected
adjuvant therapy for this group. Completed therapy, the flap will be positioned in the same
place of origin and stabilized with simple sutures through wire Vicryl 5-0. In order to avoid
painful symptoms will be prescribed analgesics (Paracetamol 750mg, 01 tablet every 6 hours
for 48 hours). They will also be prescribed soft oral rinses with 0.12% chlorhexidine
digluconate, 2 times a day for 14 days. The sutures are removed after 7 days. Being performed
weekly supragingival plaque control in the first month and monthly until completing 3 after
surgical intervention months.
Antimicrobial photodynamic Therapy
After surgical access and realization of flap RARÎ, surgical sites selected to receive the
TfdA will be irrigated with saline will be dried with sterile gauze, a period of 10 minutes
and waited, until there is no more bleeding. Soon after, will be applied fotossintentizador
hydrochloride phenothiazine, whose main component is the toluidine blue at a concentration of
10mg / mL (Helbo Blue, Helbo Photodynamic Sytems, Grieskirchen, Austria), which will be in
contact for 3 minutes. Posteriorly, irrigation will be performed with saline solution for
removal of the excess fotossensitizador and colored areas are irradiated with a laser diode
of wavelength 660 nm, maximum power 60 mW / cm2 and an energy density of 0,6J / cm2 ( Helbo
therapielaser, Helbo Photodynamic Systems GmbH & Co KG, Grieskirchen, Austria), for 60
seconds per site. The treatment is carried out in 6 sites on the teeth, totaling six minutes
of application of laser light per tooth. Teeth with furcation lesion will increase more 60
seconds into the lesion.
Each patient will be impressed with alginate in order to obtain models of the dental arches
and elaborate a guide plate made of acetate. This plate will present grooves that will be
used as references to standardize the insertion and tilt of the automated periodontal probe
(Florida Probe System, Florida Probe Corporation, Gainesville, FL, USA). The visible plaque
index for each patient, rated dichotomously (O'Leary et al. 1972), will be determined by the
percentage of tooth surfaces with deposits of plaque stained with disclosing solution.
Post-surgical protocol
Treatment with TFDa in the Test Group maintained the protocol of applications in the periods
of 2, 7 and 14 days post-surgical intervention as described by (Ramos et al., 2016). This
protocol is distinct from the previous one by the time of exposure to laser light. In the
protocol described above, the exposure time is 60 seconds per site totaling 6 minutes. In
this, the applications are only 10 seconds per site at 6 sites per tooth, totaling 1 minute
of exposure. Teeth involving bifurcation lesion had an additional 10 seconds inside the
lesion.
Clinical monitoring
The following clinical periodontal parameters will be assessed at 6 sites of each tooth
(mesio-buccal, buccal, disto-buccal, mesio-lingual, lingual and disto-lingual): (i) probing
pocket depth (PPD): it will be measured from the gingival margin to the bottom of the pocket;
(ii) gingival recession (GR): it will be measured from the enamelcement junction to the
bottom of the pocket; (iii) clinical attachment level (CAL): it will be measured as PPD + GR
(GR will be equal to 0 whenever the cementenamel junction is covered); (iv) bleeding on
probing (BOP): it will be evaluated dichotomously: the presence of the bleeding will be
considered positive when occurring within 30 seconds from the insertion of the probe for
probing depth; (v) Plaque index (PI): it will be evaluated dichotomously. BOP, PPD, CAL and
GR will be measured at six sites per tooth (mesio-buccal, buccal, disto-buccal,
disto-lingual, lingual and mesio-lingual). All probing measurements will be performed using
an automated periodontal probe.
The clinical periodontal parameters and the plaque index of each patient will be recorded at
baseline (pre-intervention), as well as +30 and +90 days after the surgical periodontal
therapy. The Kappa index will be used to evaluate the examiner calibration on clinical
periodontal parameters collection in order to calculate the intra-examiner agreement.
According to the World Health Organization (WHO) criteria for diagnosis, the acceptable Kappa
index of agreement must be greater than or equal to 0.85 (WHO, 1997). This level of agreement
will be used for calibration of the examiner in this project. Ten patients, each one showing
at least two pairs of contralateral single-rooted teeth with PD ≥ 5 mm on interproximal
sites, will be selected to calibrate the examiner. Each patient will be evaluated on two
separate occasions 48 hours apart in order to obtain the intra-examiner reliability through
the Kappa index.
Microbiological monitoring
At baseline and +30 and +90 days after the surgical periodontal therapy, samples of
subgingival plaque will be obtained from eight interproximal sites of each patient. Samples
will be individually analyzed for their content of 40 subgingival bacterial species using the
checkerboard DNA-DNA hybridization technique (Socransky et al., 2004a; Socransky et al.,
2004b). The selected teeth will be isolated with sterile cotton rolls and dried with air
jets. Then, the supragingival plaque will be carefully removed using a sterile curette.
Another sterile curette will be used to collect the subgingival plaque, starting from the
bottom of the periodontal pocket to its coronal portion. The samples will be stored in
sterilized Eppendorf tubes and will be processed at the Microbiology Laboratory of the
Guarulhos University (UNG, Guarulhos, SP, Brazil).
Statistical analysis
The normality and homoscedasticity of the data obtained will be checked. Comparisons within
groups and among groups at different time intervals will be performed through parametric or
non-parametric appropriate tests. The significance level will be set at 5% in all tests. All
calculations will be performed by SPSS software (SPSS, Chicago IL, USA).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06400069 -
Role of NLRP6 in Chronic Periodontitis
|
||
Completed |
NCT05231096 -
Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis
|
N/A | |
Completed |
NCT03203746 -
Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Completed |
NCT02516111 -
Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment
|
Phase 2/Phase 3 | |
Completed |
NCT02174146 -
Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy
|
N/A | |
Terminated |
NCT02568163 -
Influence of Stress on Non Surgical Periodontal Treatment
|
N/A | |
Completed |
NCT02430519 -
Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects
|
N/A | |
Completed |
NCT01233765 -
Analysis of Neutrophil Response in Chronic Periodontitis
|
N/A | |
Completed |
NCT01438333 -
Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection
|
N/A | |
Completed |
NCT02218515 -
Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft
|
Phase 4 | |
Completed |
NCT02197260 -
Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing
|
Phase 4 | |
Not yet recruiting |
NCT03270280 -
Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis
|
Phase 2 | |
Not yet recruiting |
NCT04026828 -
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
|
||
Completed |
NCT04697199 -
The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis
|
Phase 1 | |
Completed |
NCT04643288 -
Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects
|
N/A | |
Completed |
NCT03039244 -
Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers
|
N/A | |
Completed |
NCT02518152 -
Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis
|
Phase 2/Phase 3 | |
Completed |
NCT02898675 -
Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing
|
N/A | |
Completed |
NCT02851823 -
Combined Use of Er:YAG and Nd:YAG Laser
|
N/A |